Search

Expert Perspectives Series – Usher Syndrome and Retinitis Pigmentosa

Webcast

ProQR Expert Perspectives Series on Usher Syndrome and Retinitis Pigmentosa

June 22, 2020
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

Press release

… in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, …

December 16, 2021
Eye on the Future Forum - Spring Summit

Webcast

The EFF Spring Virtual Summit hosted by ProQR on April 15 is a virtual meeting featuring the latest clinical data for USH2A mediated Usher syndrome and retinitis pigmentosa and a live panel discussion.

April 15, 2021
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

… Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, …

November 21, 2019
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

… Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. …

September 09, 2019
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Press release

… Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, …

December 11, 2019
ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Press release

… Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) LEIDEN, Netherlands and CAMBRIDGE, Mass., …

August 12, 2019
Fall Eye on the Future Forum (EFF) Summit 2020

Virtual Congress

The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR

September 23, 2020
ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

Press release

… QR-421a Designation is for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene …

January 30, 2020
ProQR update and additional sepofarsen Illuminate trial analyses

News update

… (QR-421a) program for USH2A -mediated Usher syndrome and retinitis pigmentosa on a single Phase 2/3 Sirius trial with the …

April 13, 2022